Various Pharmacos R&D Focus Discussed by Global Markets Direct Now Available at MarketPublishers.com

31 Mar 2016 • by Natalie Aster

LONDON – TD The Market Publishers, Ltd. is happy to announce that in-demand company research reports developed by Global Markets Direct have been recently uploaded to its catalogue.

These comprehensive research reports provide in-depth analyses of the various pharma companies’ pipeline therapeutic landscape. Each study gives a detailed overview of the company in question; contains descriptive profiles for the pertinent pipeline drug products; explores a number of key pipeline products based on different stages of development ranging from discovery till pre-registration; evaluates the firm’s pipeline therapeutics on the basis of drug target, MoA, RoA and molecule type. Each publication features the respective company’s outlicensed and partnered product line and also provides a summary of the dormant and discontinued drugs that have gone inactive over time. The reports cast light on R&D development progress, uncover the latest statements, news and deals related to the pharmacos discussed.

Companies analysed in the reports encompass:

• Ensol Biosciences Inc
• Heptares Therapeutics Limited
• Jyant Technologies, Inc
• Selvita S.A.
• Bolder Biotechnology, Inc
• Bharat Biotech International Limited
• Immatics Biotechnologies GmbH

Reasons to Buy:

• evaluate the respective firm’s strategic position with complete access to granular information on its product pipeline;
• obtain strategically vital competitor information, study, and insights to devise effective R&D strategies;
• detect emerging players with likely strong product portfolio and formulate effective counterstrategies to gain a competitive edge;
• get an understanding of key and various types of therapeutics at the developmental stage for the respective company;
• discover potential novel partners or clients in the target demographic;
• effectively plan M&As by identifying top players and the most promising therapeutics in clinical trials;
• elaborate corrective measures for pipeline projects by understanding the firm’s pipeline depth as well as pipeline therapeutics’ focus;
• develop and devise in- and out-licensing strategies by detecting prospective partners with the most interesting projects.

More studies by the publisher can be found at Global Markets Direct page. 

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 
MarketPublishers.com